In this issue of JAMA Cardiology, Goldstein et al1 report on a prespecified analysis of the previously published Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3 (MOMENTUM III) trial.2 Their results suggest that older, well-known indications for left ventricular assist device (LVAD) implant in patients with advanced heart failure, bridge to transplant (BTT) and destination therapy (DT), are no longer clinically distinctive in the current era of durable mechanical circulatory support (MCS).
Anderson AS. At Last, One Indication for Left Ventricular Assist Devices—A Bridge to a Better and Longer Life. JAMA Cardiol. 2020;5(3):251–252. doi:10.1001/jamacardio.2019.5592
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: